Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15110)	2/14/1998 10:45:00 PM
From: J Stone	Respond to of 32384

Henry, Would you refresh my memory as to the status of current trials with Targretin for diabetes? My biochemistry days ended almost twenty years ago, and while I've forgotten most of what I was taught I still recall that the renal systems of mice and rats are so similar to humans that drugs that work well on diabetic mice have a probability of 99+% of being effective on humans. So even if Targretin's breast cancer effectiveness does not match the rat results, type II diabetes is going to make Targretin a big seller. If Targretin is as effective in humans, great for women and their families and great for us. Thanks. Jeff